HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

NUTX

Nutex Health Inc. (NASDAQ)

Healthcare — Medical Care Facilities

Nutex Health Inc. operates as a healthcare services and operations company in the United States. It operates through three segments: Hospital, Population Health Management (PHM), and Real Estate. The Hospital segment develops and operates a network of micro hospitals, specialty hospitals, and hospital outpatient departments that offer healthcare services, including emergency room care, inpatient care, and behavioural health. It also provides imaging services, such as CT scan, X-ray, MRI, ultrasound, etc.; laboratory services; and onsite inpatient pharmacies. The PHM segment provides management, administrative, and other support services to its affiliated hospitals and physician groups by establishing and operating provider networks, such as independent physician associations (IPAs); and a cloud-based technology platform for IPAs. The Real Estate segment owns and leases land and hospital buildings. Nutex Health Inc. was founded in 2011 and is headquartered in Houston, Texas.

Strong Buy 1.2 / 5 5 analysts
$190.71
+$19.82 (+11.60%)
Target: $246.40 (29.2%)
Sign in to add NUTX to a watchlist or set price alerts.

Price History

52-Week Range

Fundamentals

Market Cap$1.31B
P/E Ratio (TTM)13.95
Forward P/E9.38
EPS (TTM)$13.67
Dividend Yield-
Profit Margin10.95%
Revenue Growth2.20%
ROE53.65%
Debt/Equity78.97
Recommendation Strong Buy 1.2
Analyst Target$246.40
Analysts5
Indexes NASDAQ

Technical Indicators

RSI (14)88.1
Beta2.06
SMA 20-
SMA 40-
52-Week High$193.07
52-Week Low$77.21
50-Day Avg$133.84
200-Day Avg$125.96
Avg Volume157.9K
Volume215.0K

Performance Analysis

BULLISH

NUTX shows predominantly bullish signals based on its fundamentals and technicals.

- Trading near its 52-week high ($193.07), which may indicate limited upside.
- RSI at 88.1 indicates overbought conditions — a pullback may be due.
+ Price is above both the 50-day and 200-day moving averages — strong uptrend.
+ P/E of 14.0 suggests the stock may be undervalued.
~ Modest revenue growth of 2.2% year-over-year.
+ Wall Street consensus is "Strong Buy" from 5 analysts.
+ Average analyst target of $246.40 implies 29.2% upside.

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Jul 02, 2026 13:23 UTC

Back to Screener Export Report